-
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation
-
Ultimovacs Announces Notice of Resignation from Deputy Board Member
-
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer
-
Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024
-
Ultimovacs ASA announces revised terms of the employee share option program
-
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab
-
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
-
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
